Logo image of AELIS.PA

AELIS FARMA SAS (AELIS.PA) Stock Fundamental Analysis

Europe - EPA:AELIS - FR0014007ZB4 - Common Stock

1.095 EUR
+0 (+0.46%)
Last: 11/18/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, AELIS scores 2 out of 10 in our fundamental rating. AELIS was compared to 75 industry peers in the Biotechnology industry. Both the profitability and financial health of AELIS have multiple concerns. AELIS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AELIS had negative earnings in the past year.
AELIS had a negative operating cash flow in the past year.
In the past 5 years AELIS reported 4 times negative net income.
AELIS had negative operating cash flow in 4 of the past 5 years.
AELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFAELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

1.2 Ratios

AELIS has a Return On Assets of -52.61%. This is in the lower half of the industry: AELIS underperforms 68.00% of its industry peers.
AELIS's Return On Equity of -134.05% is in line compared to the rest of the industry. AELIS outperforms 42.67% of its industry peers.
Industry RankSector Rank
ROA -52.61%
ROE -134.05%
ROIC N/A
ROA(3y)-31.08%
ROA(5y)-24.2%
ROE(3y)-61.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AELIS.PA Yearly ROA, ROE, ROICAELIS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

AELIS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AELIS.PA Yearly Profit, Operating, Gross MarginsAELIS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

AELIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
AELIS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AELIS has been increased compared to 5 years ago.
Compared to 1 year ago, AELIS has a worse debt to assets ratio.
AELIS.PA Yearly Shares OutstandingAELIS.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AELIS.PA Yearly Total Debt VS Total AssetsAELIS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

A Debt/Equity ratio of 0.74 indicates that AELIS is somewhat dependend on debt financing.
The Debt to Equity ratio of AELIS (0.74) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.29%
AELIS.PA Yearly LT Debt VS Equity VS FCFAELIS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 3.18 indicates that AELIS has no problem at all paying its short term obligations.
The Current ratio of AELIS (3.18) is better than 66.67% of its industry peers.
AELIS has a Quick Ratio of 3.18. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.18, AELIS is in the better half of the industry, outperforming 68.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 3.18
AELIS.PA Yearly Current Assets VS Current LiabilitesAELIS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AELIS have decreased strongly by -13.00% in the last year.
AELIS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -94.09%.
The Revenue for AELIS have been decreasing by -33.42% on average. This is quite bad
EPS 1Y (TTM)-13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.8%
Revenue 1Y (TTM)-94.09%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, AELIS will show a very strong growth in Earnings Per Share. The EPS will grow by 146.58% on average per year.
Based on estimates for the next years, AELIS will show a very strong growth in Revenue. The Revenue will grow by 88.24% on average per year.
EPS Next Y-131.58%
EPS Next 2Y70.14%
EPS Next 3Y146.58%
EPS Next 5YN/A
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AELIS.PA Yearly Revenue VS EstimatesAELIS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
AELIS.PA Yearly EPS VS EstimatesAELIS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 1 2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AELIS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 6.25, the valuation of AELIS can be described as very cheap.
Based on the Price/Forward Earnings ratio, AELIS is valued cheaply inside the industry as 98.67% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of AELIS to the average of the S&P500 Index (34.98), we can say AELIS is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 6.25
AELIS.PA Price Earnings VS Forward Price EarningsAELIS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AELIS.PA Per share dataAELIS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as AELIS's earnings are expected to grow with 146.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.14%
EPS Next 3Y146.58%

More info and screens

0

5. Dividend

5.1 Amount

AELIS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AELIS FARMA SAS

EPA:AELIS (11/18/2025, 7:00:00 PM)

1.095

+0 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners25.12%
Inst Owner ChangeN/A
Ins Owners17.74%
Ins Owner ChangeN/A
Market Cap15.01M
Revenue(TTM)446.00K
Net Income(TTM)-8.20M
Analysts84.44
Price Target11.22 (924.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)56.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.25
P/S 33.66
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 2.53
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)0.18
Fwd EY15.99%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.03
BVpS0.45
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.61%
ROE -134.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.08%
ROA(5y)-24.2%
ROE(3y)-61.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.44%
Cap/Sales 6.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 3.18
Altman-Z N/A
F-Score2
WACC7.29%
ROIC/WACCN/A
Cap/Depr(3y)106.33%
Cap/Depr(5y)205.47%
Cap/Sales(3y)3.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.8%
EPS Next Y-131.58%
EPS Next 2Y70.14%
EPS Next 3Y146.58%
EPS Next 5YN/A
Revenue 1Y (TTM)-94.09%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A
EBIT growth 1Y-6.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-115.71%
EBIT Next 3Y152.58%
EBIT Next 5YN/A
FCF growth 1Y40.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.71%
OCF growth 3YN/A
OCF growth 5YN/A

AELIS FARMA SAS / AELIS.PA FAQ

What is the fundamental rating for AELIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA.


What is the valuation status for AELIS stock?

ChartMill assigns a valuation rating of 3 / 10 to AELIS FARMA SAS (AELIS.PA). This can be considered as Overvalued.


How profitable is AELIS FARMA SAS (AELIS.PA) stock?

AELIS FARMA SAS (AELIS.PA) has a profitability rating of 0 / 10.


How financially healthy is AELIS FARMA SAS?

The financial health rating of AELIS FARMA SAS (AELIS.PA) is 3 / 10.